This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Bionor Pharma ASA ("BIONOR") has terminated the market making agreement with Sparebank1 Markets for the company`s shares. The market making agreement will be effective until end of August 2012.
Bionor Pharma is one of the most actively traded stocks at the OSE related to its share capital. The Company expects this trend to continue going forward.
Bionor Pharma is one of the most actively traded stocks at the OSE related to its share capital. The Company expects this trend to continue going forward.
Contact information: Bionor Pharma Oslo: +47 23010960
Steen Krøyer, CEO
Gunnar Flåten, SVP Finance & Administration, +47 91316479